Quick Answer
Vivani Medical, Inc. reported Research And Development Expense of $18.13 million for the year ending 2025.
- Vivani Medical, Inc. showed an increase of +15.1% in Research And Development Expense from 2024 to 2025.
- This data is from Vivani Medical, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $1.04 million | Q2 2014: $1.22 million | Q3 2014: $1.42 million | Q1 2015: $1.0 thousand | Q2 2015: $849.0 thousand | Q3 2015: $593.0 thousand | Q1 2016: $762.0 thousand | Q2 2016: $916.0 thousand | Q3 2016: $1.59 million | Q1 2017: $1.85 million | Q2 2017: $1.95 million | Q3 2017: $1.83 million | Q1 2018: $2.47 million | Q2 2018: $2.42 million | Q3 2018: $2.67 million | Q1 2019: $2.18 million | Q2 2019: $3.44 million | Q3 2019: $3.38 million | Q1 2020: $3.89 million | Q2 2020: $323.0 thousand | Q3 2020: $279.0 thousand | Q1 2021: $334.0 thousand | Q2 2021: $695.0 thousand | Q3 2021: $2.87 million | Q1 2022: $2.68 million | Q2 2022: $3.20 million | Q3 2022: $3.86 million | Q1 2023: $3.96 million | Q2 2023: $3.86 million | Q3 2023: $4.44 million | Q1 2024: $3.73 million | Q2 2024: $3.51 million | Q3 2024: $4.20 million | Q1 2025: $4.22 million | Q2 2025: $4.76 million | Q3 2025: $4.52 million.
- Over the full 13 years of available data (2013 to 2025), Vivani Medical, Inc.'s Research And Development Expense has grown by 457.9%.
- Historical annual values: Fiscal year 2025: $18.13 million | Fiscal year 2024: $15.75 million | Fiscal year 2023: $16.97 million | Fiscal year 2022: $14.17 million | Fiscal year 2021: $11.00 million | Fiscal year 2020: $4.84 million | Fiscal year 2019: $13.14 million | Fiscal year 2018: $10.01 million | Fiscal year 2017: $7.89 million | Fiscal year 2016: $5.35 million | Fiscal year 2015: $3.04 million | Fiscal year 2014: $5.04 million | Fiscal year 2013: $3.25 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: